Primary breast lymphoma: a single institution's experience.
10.4174/jkss.2013.84.5.267
- Author:
Seung Pil JUNG
1
;
Minkuk KIM
;
Kang Min HAN
;
Jung Han KIM
;
Jee Soo KIM
;
Seok Jin NAM
;
Jeoung Won BAE
;
Jeong Eon LEE
Author Information
1. Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jeongeon.lee@samsung.com
- Publication Type:Original Article
- Keywords:
Breast;
Diffuse large B-cell lymphoma;
Combined modality therapy;
Treatment outcome
- MeSH:
Accounting;
Antibodies, Monoclonal, Murine-Derived;
B-Lymphocytes;
Biopsy;
Biopsy, Large-Core Needle;
Breast;
Combined Modality Therapy;
Female;
Follow-Up Studies;
Humans;
Korea;
Lymphoma;
Lymphoma, B-Cell;
Mastectomy, Segmental;
Medical Records;
Nitriles;
Prognosis;
Pyrethrins;
Rare Diseases;
Recurrence;
Retrospective Studies;
Rituximab;
Sentinel Lymph Node Biopsy;
Treatment Outcome
- From:Journal of the Korean Surgical Society
2013;84(5):267-272
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Primary breast lymphoma is a very rare disease, accounting for 0.4-0.5% of all breast malignancies. Due to the rarity, there are only limited reports of this disease in Korean women. In this reason, we report the experience of a single institution in Korea with primary breast lymphoma (PBL). METHODS: We retrospectively reviewed the medical records of 9 patients with PBL and evaluated the clinicopathologic characteristics and treatment outcomes. RESULTS: All nine patients were female and had diffuse large B-cell lymphoma (DLBL). The median age at diagnosis was 47.9 years and the median tumor size was 3.8 cm in diameter. The most common symptom was a painless palpable mass. Five patients were classified as stage IEA and four patients were IIEA according to the Ann Arbor staging system. Four patients underwent excisional biopsy and one patient underwent a lumpectomy with sentinel lymph node biopsy due to uncertain histology of the preoperative core needle biopsy. Nine patients received anthracycline containing combined chemotherapy; among them, five patients were treated with a rituximab containing regimen. Four patients received radiotherapy combined with chemotherapy. A complete response was achieved in eight patients. During the 44 months of the median follow-up period, three cases of relapse occurred, and among them, two patients died due to disease progression. CONCLUSION: Most PBLs are B-cell origin, with DLBL being the most common histologic type. A combined treatment modality has been known to have positive effects on prognosis, and surgery should be limited to a diagnostic purpose.
